Australia’s Biota, GSK Settle Dispute Over Relenza Promotion
This article was originally published in PharmAsia News
Biota Holdings of Australia and GlaxoSmithKline have reached a $19 million settlement of a dispute over GSK's method of promoting the Australian firm's Relenza (zanamivir) flu drug. Biota had licensed the drug to GSK for global marketing in 2000, but later accused the U.K. firm of failing to promote it properly. Biota sued GSK for $683 million, but settled for less based on advice a trial would be delayed for a long time at greater cost and risk to Biota. Biota said the two firms would resume their cooperation in promoting the drug. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.